Athenex Inc
F:2MT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Scicom (Msc) Bhd
KLSE:SCICOM
|
MY |
|
Anheuser-Busch Inbev SA
MIL:1ABI
|
BE |
|
Petronet LNG Ltd
NSE:PETRONET
|
IN |
|
R
|
Raymond Industrial Ltd
HKEX:229
|
HK |
|
F
|
Finolex Cables Ltd
BSE:500144
|
IN |
|
Systex Corp
TWSE:6214
|
TW |
Athenex Inc
Operating Expenses
Athenex Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Athenex Inc
F:2MT
|
Operating Expenses
-$96.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$22.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$14.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$5.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$8.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
See Also
What is Athenex Inc's Operating Expenses?
Operating Expenses
-96.6m
USD
Based on the financial report for Dec 31, 2022, Athenex Inc's Operating Expenses amounts to -96.6m USD.
What is Athenex Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
5%
Over the last year, the Operating Expenses growth was 32%. The average annual Operating Expenses growth rates for Athenex Inc have been 14% over the past three years , 5% over the past five years .
